Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.73 |
| ▸ | SCN8A | Q9UQD0 | 5/20 | 0.51 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913105 | 0.84 | CHRM2 (0.77) | CHRM2SCN8ACA12CA2CA9 | |
| SCHEMBL5013296 | 0.83 | CHRM2 (0.76) | CHRM2SCN8ACA12CA2CA9 | |
| SCHEMBL4912089 | 0.82 | CHRM2 (0.81) | CHRM2CA12CA2TSHRHTT | |
| SCHEMBL4916612 | 0.82 | CHRM2 (0.81) | CHRM2CA12CA2TSHRHTT | |
| SCHEMBL5034679 | 0.82 | CHRM2 (0.81) | CHRM2CA12CA2TSHRHTT | |
| SCHEMBL14399064 | 0.81 | CHRM2 (0.73) | CHRM2SCN8ACA12CA2CA9 | |
| SCHEMBL8616255 | 0.81 | CHRM2 (0.73) | CHRM2SCN8ACA12CA2CA9 | |
| SCHEMBL5769664 | 0.81 | CHRM2 (0.73) | CHRM2SCN8ACA12CA2CA9 | |
| SCHEMBL4917141 | 0.81 | CHRM2 (0.72) | CHRM2SCN8ACA12CA2CA9 | |
| SCHEMBL7605778 | 0.80 | CHRM2 (0.83) | CHRM2CA12CA2CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1638944-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000821-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | CHRM2 1393/4885SCN8A 478/4885CA12 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.